EHA 2012

 
 
 

The 17th Annual Congress of the European Hematology Association took place June 14-17, 2012, in Amsterdam, The Netherlands.

 

Nanobody can treat/prevent TTP in baboons

Jen Smith Read Article
Published: 06/28/12

baboons_mother_and_child_at_Lake_Manayara_Natl_Park_in_Tanzania_Credit_Charles_J_Sharp_230.jpg
Baboons in Tanzania
Credit: Charles J. Sharp

Results of a preclinical, industry-run study indicate that a novel nanobody can reverse and prevent the symptoms of acquired thrombotic thrombocytopenic purpura (TTP). The nanobody—called ALX-0681—prevented and fully reversed thrombocytopenia and schistocytic hemolytic anemia in baboon models. And the drug did not confer an increased risk of bleeding, brain injury, or renal failure. Filip Callewaert, PhD, a researcher at Ablynx NV, the Belgium-based company . . . [Read Article]

Gene sequencing reveals complex architecture of MM

Jen Smith Read Article
Published: 06/27/12

Bolli_Niccolo_240.jpg
Niccolò Bolli, MD, PhD

Using whole-exome sequencing, researchers have gained new insight into the clonal architecture of multiple myeloma (MM). The investigators also uncovered new information about the role of BRAF in MM. And both of these findings likely have important clinical implications, according to Niccolò Bolli, MD, PhD, of the University of Cambridge in the UK. Dr Bolli presented the findings at the 17th Annual Congress of the European Hematology Association as abstract 571, which was chosen as one of the meeting’s “best abstracts.”   [Read Article]

Drug for aHUS effective but expensive

Jen Smith Read Article
Published: 06/26/12

EHA_crowd_Credit_EHA_220.jpg
Attendees at the 17th Annual
Congress of the EHA
Photo courtesy of EHA

Eculizumab elicits “phenomenal” results in atypical hemolytic uremic syndrome (aHUS), according to two presentations given at the 17th Annual Congress of the European Hematology Association. But, as one speaker pointed out, the drug may prove too expensive for a lot of patients. “It’s the most expensive drug I’ve ever come across in my entire life,” said Adrian Newland, MD, of Barts and The London School of Medicine and Dentistry in the UK. [Read Article]

Team discovers novel drivers of T-ALL

Jen Smith Read Article
Published: 06/22/12

De_Keersmaecker_Kim_PhD_Credit_EHA_230.jpg
Kim De Keersmaecker, PhD
Photo courtesy of EHA

Using whole-exome sequencing, a group of researchers has identified 7 new genes as drivers of T-cell acute lymphoblastic leukemia (T-ALL). The team also uncovered differences in mutation incidence between adult patients and children with the disease. Kim De Keersmaecker, PhD, of Katholieke Universiteit Leuven in Belgium, and her colleagues conducted this research and presented their results at the 17th Annual Congress of the European Hematology Association. [Read Article]

Antibody proves active in aggressive B-cell malignancies

Jen Smith Read Article
Published: 06/21/12

EHA_2012_audience_Credit_EHA_220.jpg
Attendees at the 17th Annual
Congress of the EHA
Photo courtesy of EHA

A novel trifunctional antibody can provide relief for pediatric patients with highly refractory B-cell malignancies, a small study suggests. The antibody, called FBTA05, elicited complete responses in 5 of 10 patients with heavily pretreated non-Hodgkin lymphoma or acute leukemia. The drug also enabled long-term survival in 2 patients and was generally well-tolerated. Friedhelm Schuster, MD, PhD, presented these results at the 17th Annual Congress of the European Hematology Association. [Read Article]

Mechanism of bone marrow failure in FA revealed

Jen Smith Read Article
Published: 06/21/12

Ceccaldi_Raphael_PharmD_Credit_EHA_230.jpg
Raphael Ceccaldi, PharmD
Photo courtesy of EHA

Investigators have uncovered a mechanism that is central to bone marrow failure in Fanconi anemia (FA), according to results presented at the 17th Annual Congress of the European Hematology Association. The researchers say they have identified a p53/p21 response to cellular stress and DNA damage that leads to progressive hematopoietic stem and progenitor cell (HSPC) elimination in FA patients. And there is evidence to suggest that similar mechanisms could be at play . . .  [Read Article]

Cardiac iron overload in thalassemia varies by region

Jen Smith Read Article
Published: 06/20/12

Carpenter_Jean_Paul_MD_EHA_2012_240.jpg
Jean-Paul Carpenter, MD

Results of an international survey indicate the overall incidence of myocardial iron overload in thalassemia patients is rather high, but there are significant differences among geographical regions. Researchers analyzed cardiovascular magnetic resonance (CMR) T2* data from thalassemia patients treated at 34 medical centers around the world. And the data revealed that 42.5% of patients had “significant cardiac iron.” But there was also a significant difference between . . . [Read Article]

Speaker offers novel insights into HSC differentiation

Jen Smith Read Article
Published: 06/19/12

EHA_2012_crowd_230.jpg
Attendees at the 17th Annual
Congress of the EHA

New research suggests the “battle” between GATA-1 and PU.1 is not required for hematopoietic stem cell (HSC) lineage choice. Both transcription factors appear to be involved in the execution of HSC lineage choice, according to the research. But the ultimate “decision” is not dependent upon GATA-1 or PU.1 expression. Timm Schroeder, PhD, discussed this discovery during the first plenary session of the 17th Congress of the European Hematology Association. [Read Article]

How tumor cells evade T cells

Jen Smith Read Article
Published: 06/19/12

ramsay_alan_EHA_2012_240.jpg
Alan G. Ramsay, PhD

Researchers say they have identified a set of molecules that enable cancer progression by allowing tumor cells to evade T cells. The team found that these 4 molecules—CD200, PD-L1, B7-H3, and TNFRSF14—are key mediators of the T-cell synapse defect in leukemias, lymphomas, and solid tumor malignancies. But experiments revealed that targeted monoclonal antibodies and the immunomodulatory agent lenalidomide can counteract the molecules’ effects. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}